Data recently unveiled showed GSK’s respiratory syncytial virus (RSV) vaccine was 82.6% effective in a keenly watched late-stage study involving older adults.
Besides reducing the burden of participation, sponsors benefit from lower costs and faster timelines. In addition, when patients are more engaged, patient protocol compliance increases.
Nimbus Therapeutics scored a $496 million payday through a collaboration and licensing deal with pharma giant Eli Lilly for potential therapeutics for metabolic diseases, the companies announced Tuesday.
Merck & Co. Inc. opted to jointly develop and potentially sell a personalized mRNA vaccine with Moderna Inc. for a $250 million upfront payment on Wednesday, sending the vaccine maker’s shares up over 8%.
Bayer subsidiary Vividion Therapeutics and precision oncology company Tavros Therapeutics entered into a five-year collaboration agreement, valued at up to $930 million, to discover and develop four novel oncology targets.
Novavax Inc. said on Wednesday data from studies in adults and adolescents showed that the booster dose of its COVID vaccine produced robust antibodies against several Omicron variants, including BA.1, BA.2 and BA.5.
World Health Organization head Tedros Adhanom Ghebreyesus said on Wednesday a clinical trial of vaccines that could potentially combat the Sudan strain of Ebola driving an outbreak in Uganda could start within weeks.
An influential panel of U.S. experts recommended for the first time on Tuesday that primary care doctors screen all children ages 8 to 18 for anxiety, even if there are no symptoms.
Data from an ongoing Phase III trial showed Sanofi/Regeneron’s Dupixent (dupilumab) can induce histological disease remission in young eosinophilic esophagitis (EoE) patients ages 1–11 years, the companies announced Tuesday.
Evommune’s novel human tissue-based assay system is proving to be a key differentiator as the company develops therapies to control chronic inflammation in autoimmune diseases.
